Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
ImmunityBio's Anktiva shows high complete response rates in trials, enhancing immunotherapy for BCG-unresponsive bladder ...
Parade on MSN8d
This Is One of the Most Common Signs of Bladder Cancer, According to a UrogynecologistBladder cancer makes up about 4% of cancers, most commonly affecting people 55 and older. While rates for bladder cancer are ...
PJ DiPentino felt uneasy about his local oncologist’s plan. DiPentino’s bladder cancer had returned in a lymph node, and the ...
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...
With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback